126645-75-8

Basic information

• Product Name: (4-BENZYL-MORPHOLIN-2-YLMETHYL)-METHYL-AMINE
• Synonyms: (4-BENZYL-MORPHOLIN-2-YLMETHYL)-METHYL-AMINE;(4-BENZYLMORPHOLIN-2-YL)-N-METHYL METHANAMINE;2-Morpholinemethanamine, N-methyl-4-(phenylmethyl)-;1-(4-BenzylMorpholin-2-yl)-N-MethylMethanaMine;N-Methyl-4-benzyl-2-morpholinemethanamine 2HCl
• CAS NO: 126645-75-8
• Molecular Formula: C₁₃H₂₀N₂O
• Molecular Weight: 220.31
• Mol File: 126645-75-8.mol

Chemical Properties

• Appearance: /
• Refractive Index: 1.528
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: (4-BENZYL-MORPHOLIN-2-YLMETHYL)-METHYL-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (4-BENZYL-MORPHOLIN-2-YLMETHYL)-METHYL-AMINE(126645-75-8)
• EPA Substance Registry System: (4-BENZYL-MORPHOLIN-2-YLMETHYL)-METHYL-AMINE(126645-75-8)

Safety Data

• Hazardous Substances Data: 126645-75-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(4-Benzyl-morpholin-2-ylmethyl)-methyl-amine is utilized as a reagent in organic synthesis for the preparation of a variety of organic compounds. Its unique structure allows for the creation of new chemical entities with potential applications in various industries.
Used in Pharmaceutical Development:
In the pharmaceutical industry, (4-Benzyl-morpholin-2-ylmethyl)-methyl-amine has been studied for its potential pharmacological properties. It shows promise as an antipsychotic and antidepressant agent, offering new avenues for the treatment of mental health disorders.
Used in Coordination Chemistry:
(4-Benzyl-morpholin-2-ylmethyl)-methyl-amine has also been investigated for its potential use as a ligand in coordination chemistry. Its ability to form stable complexes with metal ions can lead to the development of new materials with unique properties and applications.
Used in Heterocyclic Compound Synthesis:
Furthermore, this compound serves as a building block in the synthesis of heterocyclic compounds, which are important in various fields such as pharmaceuticals, agrochemicals, and materials science. Its versatility in forming heterocyclic structures contributes to the discovery of novel compounds with potential applications.

InChI:InChI=1/C13H20N2O/c1-14-9-13-11-15(7-8-16-13)10-12-5-3-2-4-6-12/h2-6,13-14H,7-11H2,1H3

Upstream product

• 40987-25-5 N-benzyl-2-chloromethylmorpholine 
• 74-89-5 methylamine 
• 112913-96-9 2-(N-acetylaminomethyl)-4-benzylmorpholine 
• 147767-51-9 4-benzyl-2-cyanomorpholine 
• 126645-74-7 2-<(N-acetyl-N-methylamino)methyl>-4-benzylmorpholine 

Downstream Products

• 126645-67-8 5-amino-N-<(4-benzyl-2-morpholinyl)methyl>-5-chloro-2-methoxy-N-methylbenzamide 

Relevant articles and documents

Combination therapy with CHK1 inhibitors

Compounds of Structure I, and salts, tautomers, stereoisomers, and mixtures thereof may be used in methods of inhibiting checkpoint kinase 1 in subjects, in methods for inducing cell cycle progression, and in methods for increasing apoptosis in cells. Such compounds may be used to prepare pharmaceutical compositions and may be used in conjunction with DNA damaging agents.

Inhibition of FGFR3 and treatment of multiple myeloma

Methods of inhibiting fibroblast growth factor receptor 3 and treating various conditions mediated by fibroblast growth factor receptor 3 are provided that include administering to a subject a compound of Structure I, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I have the following structure where and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting fibroblast growth factor receptor 3 and for use in treating conditions mediated by fibroblast growth factor receptor 3 such as multiple myeloma.

BENZIMIDAZOLE QUINOLINONES AND USES THEREOF

Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes.

Novel benzamides as selective and potent gastric prokinetic agents. 1. Synthesis and structure-activity relationships of N-[(2-morpholinyl)alkyl]benzamides

With the purpose of obtaining more potent and selective gastric prokinetic agents than metoclopramide (1), a new series of N-[(2-morpholinyl)alkyl]benzamides (17-52) were synthesized and their gastric prokinetic activity was evaluated by determining effect on the gastric emptying of phenol red semisolid meal and of resin pellets solid meal in rats and mice. The morpholinyl moiety was newly designed after consideration of the side-chain structure of cisapride (2) and produced the desired activity when coupled with the 4-amino-5-chloro-2-methoxybenzoyl group of both metoclopramide and cisapride. Modification of the substituents of the benzoyl group markedly influenced the activity. In particular, 4-amino-N-[benzyl-2-morpholinyl)methyl]-5-chloro-2-methoxybenzamide (17) and the 4-(dimethylamino) and 2-ethoxy analogues (25 and 29) or 17 showed potent and selective gastric prokinetic activity along with a weak dopamine D2 receptor antagonistic activity.